Neurotoxizität unter CAR-T-Zell-Therapie (CAR: chimärer Antigenrezeptor)
作者： N. Möhn , C. Könecke , T. Skripuletz
DOI: 10.1007/S42451-020-00172-Y
关键词:
摘要: Die Therapie mit CAR-T-Zellen (CAR: chimarer Antigenrezeptor) revolutionierte die Behandlung maligner B‑Zell-Erkrankungen. Dabei werden den Patienten genetisch modifizierte korpereigene T‑Zellen reinfundiert. In Europa sind bisher 2 Praparate namens Tisagenlecleucel und Axicabtagen-Ciloleucel fur bestimmter B‑Zell-Erkrankungen zugelassen. Ansprechraten in jeweiligen Zulassungsstudien ubertrafen diejenigen nach Standardtherapie bei Weitem. Dennoch gehen derartige zellbasierte Therapien auch z. T. bedrohlichen Nebenwirkungen einher. Neben dem Zytokinfreisetzungssyndrom behandelten insbesondere neurologische Symptome unterschiedlichen Schweregrades zu beobachten. diesem Artikel sollen Charakteristika dieser neurologischen sowie Empfehlungen zum Monitoring zur der Neurotoxizitat beleuchtet werden. Zusatzlich Hypothesen Pathogenese CAR-T-Zell-assoziierten diskutiert.
springer.com
sci-hub.se 参考文章(49)
Marco L. Davila, Renier Brentjens, Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia: What are the Challenges? Hematology-oncology Clinics of North America. ,vol. 27, pp. 341- 353 ,(2013) , 10.1016/J.HOC.2012.12.004
P J Koehler, Use of corticosteroids in neuro-oncology. Anti-Cancer Drugs. ,vol. 6, pp. 19- 33 ,(1995) , 10.1097/00001813-199502000-00002
Norihiro Nishimoto, Kimio Terao, Toru Mima, Hideko Nakahara, Nobuhiro Takagi, Takahiro Kakehi, Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. ,vol. 112, pp. 3959- 3964 ,(2008) , 10.1182/BLOOD-2008-05-155846
Renier J. Brentjens, Isabelle Rivière, Jae H. Park, Marco L. Davila, Xiuyan Wang, Jolanta Stefanski, Clare Taylor, Raymond Yeh, Shirley Bartido, Oriana Borquez-Ojeda, Malgorzata Olszewska, Yvette Bernal, Hollie Pegram, Mark Przybylowski, Daniel Hollyman, Yelena Usachenko, Domenick Pirraglia, James Hosey, Elmer Santos, Elizabeth Halton, Peter Maslak, David Scheinberg, Joseph Jurcic, Mark Heaney, Glenn Heller, Mark Frattini, Michel Sadelain, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood. ,vol. 118, pp. 4817- 4828 ,(2011) , 10.1182/BLOOD-2011-04-348540
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey, Yolanda D Mahnke, Jan J Melenhorst, Susan R Rheingold, Angela Shen, David T Teachey, Bruce L Levine, Carl H June, David L Porter, Stephan A Grupp, None, Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine. ,vol. 371, pp. 1507- 1517 ,(2014) , 10.1056/NEJMOA1407222
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah, Seth M Steinberg, Dave Stroncek, Nick Tschernia, Constance Yuan, Hua Zhang, Ling Zhang, Steven A Rosenberg, Alan S Wayne, Crystal L Mackall, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial The Lancet. ,vol. 385, pp. 517- 528 ,(2015) , 10.1016/S0140-6736(14)61403-3
ILIA J. ELENKOV, Glucocorticoids and the Th1/Th2 balance. Annals of the New York Academy of Sciences. ,vol. 1024, pp. 138- 146 ,(2004) , 10.1196/ANNALS.1321.010
Jennifer N. Brudno, Robert P.T. Somerville, Victoria Shi, Jeremy J. Rose, David C. Halverson, Daniel H. Fowler, Juan C. Gea-Banacloche, Steven Z. Pavletic, Dennis D. Hickstein, Tangying L. Lu, Steven A. Feldman, Alexander T. Iwamoto, Roger Kurlander, Irina Maric, Andre Goy, Brenna G. Hansen, Jennifer S. Wilder, Bazetta Blacklock-Schuver, Frances T. Hakim, Steven A. Rosenberg, Ronald E. Gress, James N. Kochenderfer, Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease Journal of Clinical Oncology. ,vol. 34, pp. 1112- 1121 ,(2016) , 10.1200/JCO.2015.64.5929
Fang Chen, David T. Teachey, Edward Pequignot, Noelle Frey, David Porter, Shannon L. Maude, Stephan A. Grupp, Carl H. June, Jan J. Melenhorst, Simon F. Lacey, Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy Journal of Immunological Methods. ,vol. 434, pp. 1- 8 ,(2016) , 10.1016/J.JIM.2016.03.005
Rebecca Gardner, David Wu, Sindhu Cherian, Min Fang, Laïla-Aïcha Hanafi, Olivia Finney, Hannah Smithers, Michael C. Jensen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy Blood. ,vol. 127, pp. 2406- 2410 ,(2016) , 10.1182/BLOOD-2015-08-665547